Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities
This study demonstrates the potential therapeutic utility of inhibiting constitutively active AR-V signaling by disrupting coactivator binding. Such an approach is significant, as AR-Vs are emerging as important drivers of CRPC that are particularly recalcitrant to current therapies. Mol Cancer Res; 15(11); 1469–80. ©2017 AACR.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Magani, F., Peacock, S. O., Rice, M. A., Martinez, M. J., Greene, A. M., Magani, P. S., Lyles, R., Weitz, J. R., Burnstein, K. L. Tags: Cell Death and Survival Source Type: research
More News: Cancer | Cancer & Oncology | Lymphoma | Mergers and Aquisitions | Prostate Cancer | Study